Bijuva® is intended for the « natural» treatment of estrogen deficiency symptoms. It combines the two bioidentical female hormones (progesterone P4 and estradiol E2) in low doses into a single capsule. It is taken in the evening, promoting falling asleep and improving sleep disorders. The phase 3 trial, REPLENISH, randomized double-blind versus placebo-controlled, demonstrated good effectiveness on vasomotor symptoms and quality of life, as well as, over one year, its endometrial safety (no endometrial hyperplasia). Bijuva® is a non-stop continuous combination drug that minimizes blood loss and results in 90% amenorrhea at one year. It is metabolically neutral (blood glucose and cholesterol) and even beneficial in women who started it early, namely less than 6 years after menopause. Bijuva® does not affect weight or blood pressure. Despite its oral intake, it does not increase the coagulation parameters, indicating a possible neutrality on thromboembolic risk in the absence of thrombophilia or high-risk factors. In one year, Bijuva® did not increase the percentage of abnormal mammograms (Bi-Rads 3 + 4) but significantly increased the incidence of breast tenderness (10.8%). Finally, Bijuva® improved bone-remodeling markers, indicating a good probability of a preventive effect of osteoporotic fractures, similar to other HRT (hormonal replacement treatments). The availability of a bioidentical HRT, combining estradiol and progesterone in a single capsule, will certainly improve compliance and help promoting HRT rehabilitation through a neutral metabolic and oncology profile. ; SCOPUS: ar.j ; info:eu-repo/semantics/published